Logo image of BNTC

BENITEC BIOPHARMA INC (BNTC) Stock Fundamental Analysis

USA - NASDAQ:BNTC - US08205P2092 - Common Stock

13.45 USD
-0.54 (-3.86%)
Last: 9/19/2025, 8:00:01 PM
13.45 USD
0 (0%)
After Hours: 9/19/2025, 8:00:01 PM
Fundamental Rating

3

BNTC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 540 industry peers in the Biotechnology industry. BNTC has a great financial health rating, but its profitability evaluates not so good. BNTC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BNTC had negative earnings in the past year.
BNTC had a negative operating cash flow in the past year.
In the past 5 years BNTC always reported negative net income.
BNTC had a negative operating cash flow in each of the past 5 years.
BNTC Yearly Net Income VS EBIT VS OCF VS FCFBNTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M -20M

1.2 Ratios

With a decent Return On Assets value of -25.77%, BNTC is doing good in the industry, outperforming 72.04% of the companies in the same industry.
The Return On Equity of BNTC (-27.78%) is better than 79.07% of its industry peers.
Industry RankSector Rank
ROA -25.77%
ROE -27.78%
ROIC N/A
ROA(3y)-262.2%
ROA(5y)-184.58%
ROE(3y)-3486.63%
ROE(5y)-2122%
ROIC(3y)N/A
ROIC(5y)N/A
BNTC Yearly ROA, ROE, ROICBNTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BNTC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BNTC Yearly Profit, Operating, Gross MarginsBNTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K -25K

More info and screens

9

2. Health

2.1 Basic Checks

BNTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BNTC has been increased compared to 1 year ago.
Compared to 5 years ago, BNTC has less shares outstanding
BNTC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BNTC Yearly Shares OutstandingBNTC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
BNTC Yearly Total Debt VS Total AssetsBNTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

An Altman-Z score of 26.18 indicates that BNTC is not in any danger for bankruptcy at the moment.
BNTC has a better Altman-Z score (26.18) than 94.44% of its industry peers.
BNTC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 26.18
ROIC/WACCN/A
WACC9.66%
BNTC Yearly LT Debt VS Equity VS FCFBNTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 14.80 indicates that BNTC has no problem at all paying its short term obligations.
BNTC's Current ratio of 14.80 is amongst the best of the industry. BNTC outperforms 89.26% of its industry peers.
BNTC has a Quick Ratio of 14.80. This indicates that BNTC is financially healthy and has no problem in meeting its short term obligations.
BNTC's Quick ratio of 14.80 is amongst the best of the industry. BNTC outperforms 89.26% of its industry peers.
Industry RankSector Rank
Current Ratio 14.8
Quick Ratio 14.8
BNTC Yearly Current Assets VS Current LiabilitesBNTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

BNTC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 76.00%, which is quite impressive.
Looking at the last year, BNTC shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.37%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BNTC will show a very strong growth in Earnings Per Share. The EPS will grow by 22.09% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y84.99%
EPS Next 2Y34.79%
EPS Next 3Y22.09%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BNTC Yearly Revenue VS EstimatesBNTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
BNTC Yearly EPS VS EstimatesBNTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BNTC. In the last year negative earnings were reported.
Also next year BNTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNTC Price Earnings VS Forward Price EarningsBNTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNTC Per share dataBNTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as BNTC's earnings are expected to grow with 22.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.79%
EPS Next 3Y22.09%

More info and screens

0

5. Dividend

5.1 Amount

BNTC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BENITEC BIOPHARMA INC

NASDAQ:BNTC (9/19/2025, 8:00:01 PM)

After market: 13.45 0 (0%)

13.45

-0.54 (-3.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)09-24 2025-09-24/amc
Inst Owners85.4%
Inst Owner Change-42.87%
Ins Owners0.27%
Ins Owner Change0%
Market Cap353.06M
Analysts87.14
Price Target26.23 (95.02%)
Short Float %5.22%
Short Ratio23.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)45.16%
Min EPS beat(2)32.35%
Max EPS beat(2)57.97%
EPS beat(4)3
Avg EPS beat(4)-15.07%
Min EPS beat(4)-165.05%
Max EPS beat(4)57.97%
EPS beat(8)4
Avg EPS beat(8)-143.3%
EPS beat(12)5
Avg EPS beat(12)-122.43%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.25%
EPS NY rev (1m)-2.54%
EPS NY rev (3m)13.85%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.62
P/tB 3.62
EV/EBITDA N/A
EPS(TTM)-2.37
EYN/A
EPS(NY)-1.53
Fwd EYN/A
FCF(TTM)-0.71
FCFYN/A
OCF(TTM)-0.71
OCFYN/A
SpS0
BVpS3.72
TBVpS3.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.77%
ROE -27.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-262.2%
ROA(5y)-184.58%
ROE(3y)-3486.63%
ROE(5y)-2122%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.88%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.8
Quick Ratio 14.8
Altman-Z 26.18
F-Score4
WACC9.66%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.37%
EPS Next Y84.99%
EPS Next 2Y34.79%
EPS Next 3Y22.09%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-40.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.84%
EBIT Next 3Y35.42%
EBIT Next 5YN/A
FCF growth 1Y0.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.6%
OCF growth 3YN/A
OCF growth 5YN/A